Department of Dermatology, Harvard Medical School, Boston, United States; Laboratory of Immunobiology, Dana-Farber Cancer Institute, Boston, United States; Department of Medicine, Oncology, Dana-Farber Cancer Institute, Boston, United States
Department of Chemistry and Biomolecular Engineering, Vanderbilt University, Nashville, United States; Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, United States
Laboratory of Immunobiology, Dana-Farber Cancer Institute, Boston, United States; Department of Medicine, Oncology, Dana-Farber Cancer Institute, Boston, United States; Department of Medicine, Harvard Medical School, Boston, United States
Department of Biomedical Engineering, Texas A&M University, College Station, United States; Department of Materials Science & Engineering, Texas A&M University, College Station, United States; Department of Physics & Astronomy, Texas A&M University, College Station, United States
Mechanical force is critical for the interaction between an αβ T cell receptor (TCR) and a peptide-bound major histocompatibility complex (pMHC) molecule to initiate productive T-cell activation. However, the underlying mechanism remains unclear. We use all-atom molecular dynamics simulations to examine the A6 TCR bound to HLA-A*02:01 presenting agonist or antagonist peptides under different extensions to simulate the effects of applied load on the complex, elucidating their divergent biological responses. We found that TCR α and β chains move asymmetrically, which impacts the interface with pMHC, in particular the peptide-sensing CDR3 loops. For the wild-type agonist, the complex stabilizes in a load-dependent manner while antagonists destabilize it. Simulations of the Cβ FG-loop deletion, which reduces the catch bond response, and simulations with in silico mutant peptides further support the observed behaviors. The present results highlight the combined role of interdomain motion, fluctuating forces, and interfacial contacts in determining the mechanical response and fine peptide discrimination by a TCR, thereby resolving the conundrum of nearly identical crystal structures of TCRαβ-pMHC agonist and antagonist complexes.